A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer

Jiménez-López, Julia; El-Hammadi, Mazen M.; Ortíz, Raúl; Otero, María Dolores Cayero; Cabeza, Laura; Perazzoli, Gloria; Martín-Banderas, Lucía; Baeyens, José M.; Prados, José; Melguizo, Consolación

doi:10.1016/j.phrs.2019.01.013

Cited by 43 publications

(27 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighteen nude mice in each group were subcutaneously injected with 5637 cells (1 × 10 7 /0.2 ml/mouse). Next, the mice were injected with PTX (10 mg/kg, n = 06), DOX (3 mg/kg, n = 06) and PBS (n = 06) [20,21] every three days via the tail vein. The mice in the 5637 + CAF-exos group were additionally injected with CAF-exos (2-3 µg/mouse), while those in the 5637 + CAF-exos/inhi group were injected with CAF-exos/inhi (2-3 µg/mouse).…”

Section: Dual Luciferase Reporter Assaymentioning

confidence: 99%

Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN

Shan

Zhou

et al. 2021

Cell Oncol.

View full text Add to dashboard Cite

Objective Exosomes derived from cancer-associated fibroblasts (CAFs) are known as important drivers of tumor progression. Previously, microRNA (miR)-148b-3p has been found to be upregulated in bladder cancers as well as in body fluids (blood, urine) of bladder cancer patients. Here, we aimed to explore the role of CAF-derived exosome miR-148b-3p in bladder cancer progression and chemosensitivity. Methods Transwell, MTT, flow cytometry and colony formation assays were applied to assess the effects of CAF-derived exosomes on bladder cancer cell metastasis, epithelial-mesenchymal transition (EMT) and chemosensitivity. A dual luciferase reporter assay was employed to evaluate the targeting relationship between miR-148b-3p and PTEN. Gain- and loss- of function assays were conducted to explore the roles of miR-148b-3p and PTEN in the behavior of bladder cancer cells. The role of PTEN in the metastasis, EMT and chemosensitivity of bladder cancer cells was assessed both in vivo and in vitro. Results We found that CAF-derived exosomes promoted the metastasis, EMT and drug resistance of bladder cancer cells. We also found that CAF-derived exosomes could directly transport miR-148b-3p into bladder cancer cells. In a xenograft mouse model we found that CAF-derived exosomes increased miR-148b-3p expression levels and promoted tumor proliferation, metastasis and drug resistance. PTEN was validated as a target of miR-148b-3p. Concordantly, we found that PTEN overexpression inhibited EMT, metastasis and chemoresistance in bladder cancer cells, reversing the tumor promoting effects of miR-148b-3p via the Wnt/β-catenin pathway. Conclusions Our results suggest that miR-148b-3p downregulation in CAF-derived exosomes, thereby inhibiting the Wnt/β-catenin pathway and promoting PTEN expression, may offer potential opportunities for bladder cancer treatment.

show abstract

Section: Dual Luciferase Reporter Assaymentioning

confidence: 99%

Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN

Shan

Zhou

et al. 2021

Cell Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition, the results of the study show that PLGA-PTX NPs can significantly increase apoptosis and reduce the volume of tumorspheres derived from LL/2 and A549 cells. Biodistribution studies have shown that PLGA-PTX NP drug circulation time is increased when compared to free PTX; moreover, the accumulation in lung and brain tissues is greater [80]. Resistance to the tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR TKIs) in NSCLC usually appears after 9-13 months of medication.…”

Section: Nanomedicine and Anticancer Drugsmentioning

confidence: 99%

Recent applications and strategies in nanotechnology for lung diseases

et al. 2021

View full text Add to dashboard Cite

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health. However, for the treatment and diagnosis of various lung diseases, such as pneumonia, asthma, cancer, and pulmonary tuberculosis, are becoming increasingly challenging. Currently, several types of treatments and/or diagnostic methods are used to treat lung diseases; however, the occurrence of adverse reactions to chemotherapy, drug-resistant bacteria, side effects that can be significantly toxic, and poor drug delivery necessitates the development of more promising treatments. Nanotechnology, as an emerging technology, has been extensively studied in medicine. Several studies have shown that nano-delivery systems can significantly enhance the targeting of drug delivery. When compared to traditional delivery methods, several nanoparticle delivery strategies are used to improve the detection methods and drug treatment efficacy. Transporting nanoparticles to the lungs, loading appropriate therapeutic drugs, and the incorporation of intelligent functions to overcome various lung barriers have broad prospects as they can aid in locating target tissues and can enhance the therapeutic effect while minimizing systemic side effects. In addition, as a new and highly contagious respiratory infection disease, COVID-19 is spreading worldwide. However, there is no specific drug for COVID-19. Clinical trials are being conducted in several countries to develop antiviral drugs or vaccines. In recent years, nanotechnology has provided a feasible platform for improving the diagnosis and treatment of diseases, nanotechnology-based strategies may have broad prospects in the diagnosis and treatment of COVID-19. This article reviews the latest developments in nanotechnology drug delivery strategies in the lungs in recent years and studies the clinical application value of nanomedicine in the drug delivery strategy pertaining to the lung.

show abstract

“…Hence, various biomedical and pharmaceutical CTS-based microns or NPs have been developed to enhance the therapeutic effect and reduce irritant or allergic reactions (Diebold, 2010;Gonçalves, 2017). These studies inspired the present authors to use CTS and PLGA in the development of a nano-vehicle system for the dual delivery of NAT and CLZ exclusively via FDA-approved carrier materials (Castro et al, 2019;Jiménez-López et al, 2019).…”

Section: Introductionmentioning

confidence: 98%

Fabrication and Characterization of Chitosan/Poly(Lactic-Co-glycolic Acid) Core-Shell Nanoparticles by Coaxial Electrospray Technology for Dual Delivery of Natamycin and Clotrimazole

Cui

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Natamycin (NAT) is the drug of choice for the treatment of fungal keratitis (FK). However, its inherent shortcomings, such as poor solubility, high dosing frequency, and long treatment cycle, need to be urgently addressed by designing a new delivery to widen its clinical utility. Growing research has confirmed that clotrimazole (CLZ) plays a significant role in fungal growth inhibition. Hence, coaxial electrospray (CO-ES) technology is used herein to prepare nano-systems with an average hydrodynamic particle size of 309-406 nm for the co-delivery of NAT and CLZ in chitosan (CTS) and poly(lactic-co-glycolic acid) (PLGA). The resulting NAT/CLZ@CTS/PLGA formulations were characterized by a transmission electron microscope (TEM) and in vitro release test. The results show that the formulations had obvious core-shell structures, uniform particle distribution, and also can sustain the release of drugs over 36 h. Furthermore, in vitro hemolysis, in vivo corneal irritation test, local allergenic test, and antifungal activity analyses are performed to evaluate the safety and efficiency of the formulations. Thus, good biosafety along with a significant anti-candidiasis effect are found in the NAT/CLZ@CTS/PLGA nanoparticles (NPs). Taken together, the results suggest that this design may provide a promising drug delivery system and a new option for the treatment of FK.

show abstract

A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer

Cited by 43 publications

References 59 publications

Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN

Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN

Recent applications and strategies in nanotechnology for lung diseases

Fabrication and Characterization of Chitosan/Poly(Lactic-Co-glycolic Acid) Core-Shell Nanoparticles by Coaxial Electrospray Technology for Dual Delivery of Natamycin and Clotrimazole

Contact Info

Product

Resources

About